Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma | OncLive

Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma

February 11, 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

This is a phase I clinical trial evaluting an oncolytic virus reolysin in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

The goal is to find the maximum tolerated dose of reolysin. Preliminary results regarding immune system activation are promising.

The study is currently ongoing. Next steps include expanding the study to include more patients to confirm safety.


x